Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CODAMINE vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Mild to moderate pain,Cough suppression (off-label)
Relief of moderate to moderately severe pain
Adults: 1-2 tablets (codeine 30 mg + acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life: 4–6 hours in adults; prolonged to 8–12 hours in renal impairment (Cr Cl <30 m L/min)
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP2D6 to morphine (active) and CYP3A4 to norcodeine; also glucuronidation.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
~92% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Vd: 1.2 L/kg (range 0.8–1.6 L/kg), indicating extensive tissue distribution
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: 65–75% (first-pass effect); Rectal: 50–60%; Intramuscular: 90%
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
GFR 30-50 m L/min: Use with caution, reduce dose by 25-50% or extend interval to every 6-8 hours. GFR <30 m L/min: Avoid use due to risk of codeine accumulation and toxicity.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and monitor for sedation. Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Weight-based codeine dosing: 0.5-1 mg/kg every 4-6 hours as needed; maximum 60 mg per dose. Acetaminophen component: 10-15 mg/kg every 4-6 hours; maximum 75 mg/kg per day. Not recommended in children under 12 years due to risk of respiratory depression.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Start at lower end of dosing range (e.g., 1 tablet every 6 hours) due to increased sensitivity and risk of respiratory depression, constipation, and sedation. Monitor renal and hepatic function.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; AND RISK OF MEDICATION ERRORS.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Risk of respiratory depression, especially in children; ultra-rapid metabolizers (CYP2D6 duplications) may experience life-threatening toxicity; avoid use post-tonsillectomy/adenoidectomy in children; risk of opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; seizures; serotonin syndrome with serotonergic drugs; GI obstruction; impaired mental/physical abilities.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known hypersensitivity; use in children <12 years; use in children <18 years post-tonsillectomy/adenoidectomy; pregnant women during labor (prolonged use); concomitant MAOIs or within 14 days.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid grapefruit juice as it may alter metabolism of codeine. High-fiber meals may help with constipation; avoid excessive alcohol. St. John's Wort may reduce codeine efficacy.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
CODAMINE is classified as FDA Pregnancy Category D. First trimester: Associated with increased risk of cardiovascular and neural tube defects. Second trimester: Potential for fetal growth restriction and oligohydramnios. Third trimester: Risk of neonatal withdrawal, respiratory depression, and persistent pulmonary hypertension.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
CODAMINE is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.5. Breastfeeding is not recommended due to potential for infant sedation, respiratory depression, and withdrawal. If unavoidable, monitor infant for lethargy and poor feeding.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Increased clearance during pregnancy may require 20-30% dose increase to maintain therapeutic levels. Due to risk of maternal hypotension and placental hypoperfusion, use lowest effective dose with close monitoring. Consider therapeutic drug monitoring if available.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Codamine is a combination of codeine and an antihistamine (e.g., promethazine or chlorpheniramine). Caution: risk of respiratory depression, especially in elderly or with lung disease. Monitor for constipation. Avoid in children under 12 due to risk of respiratory depression. Use lowest effective dose for shortest duration. Antihistamine component may cause anticholinergic effects (dry mouth, urinary retention, blurred vision).
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Do not exceed recommended dose; risk of serious side effects like slowed breathing.,Avoid alcohol and other sedatives (benzodiazepines, sleeping pills) as they increase drowsiness and breathing problems.,Do not drive or operate machinery until you know how this medication affects you.,Take with food to reduce stomach upset; drink plenty of fluids to prevent constipation.,Stop use and seek medical help if you experience difficulty breathing, severe dizziness, or allergic reaction.,Store safely out of reach of children; dispose of unused medication properly to prevent accidental overdose.,Do not use if you have a history of drug abuse or addiction.,Inform your doctor if you are pregnant, breastfeeding, or have lung/liver/kidney/thyroid problems.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CODAMINE vs ANEXSIA, answered by our medical review team.
CODAMINE is a Opioid Analgesic Combination that works by Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CODAMINE and ANEXSIA depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CODAMINE is: Adults: 1-2 tablets (codeine 30 mg + acetaminophen 500 mg per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CODAMINE and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CODAMINE is classified as Category C. CODAMINE is classified as FDA Pregnancy Category D. First trimester: Associated with increased risk of cardiovascular and neural tube defects. Second trimester: Potential for fetal. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.